The research findings carry profound implications for cancer treatment strategies, indicating that the activation of the cGAS-STING pathway could transform the landscape of immunotherapy.

The cGAS-STING pathway facilitates crosstalk between cancer cells and the tumor microenvironment (TME). The activation of cGAS-STING promotes the release and presentation of cancer antigens ...

The researchers also wanted to activate the TRL4 pathway because it boosts the effects of STING activation. They use agonists, which are any chemicals that can trigger a biological response; in ...

Considered to be one of the greatest revolutions in cancer treatment, immunotherapy enhances the immune system's ability to ...

Researchers have developed an innovative nano-immune agonist that significantly improves immunotherapy ... the cGAS-STING signaling pathway, a key player in innate immune activation.

Growing evidence has demonstrated the effectiveness of immunotherapy in treating ... regulates the activation of the STING (stimulator of interferon genes) protein, which in turn enhances the ...

Thetis Pharmaceuticals LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...

Tumor Model of Colorectal Cancer (CRC),” TP-317 demonstrated potent anti-tumor activity and synergy with checkpoint inhibitors. Key findings include: TP-317 activated STING and IFN-γ pathways ...